☆ 4.6 Article

Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC

JOURNAL OF THORACIC ONCOLOGY (2018)

Get Full Text
Add to Collection

Journal

JOURNAL OF THORACIC ONCOLOGY
Volume 13, Issue 6, Pages E89-E91

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jtho.2018.03.013

Keywords

-

Categories

Oncology Respiratory System

Funding

  1. AIRC (Italian Association for Cancer Research), Milan [IG2017-20074]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.